All In MedTech

Device Trial Radar · NCT01773148

Access Safety and Efficacy Post Endovascular Intervention

AXERA Access Safety and Efficacy Post Endovascular INtervention

Last checked: Nov 19, 2026Latest source record: Feb 24, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

240

Planned (sponsor's estimate)

Start

Dec 2012

Primary completion

Mar 2015

Study completion Jun 2015

Sponsor

Lead sponsor
Arstasis, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jan 23, 2013

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to assess the safety and effectiveness of the AXERA Access System in subjects undergoing Common Femoral Artery (CFA) access for Percutaneous Coronary Intervention (PCI) and/or Peripheral Vascular Intervention (PVI) through a 5 French (F) or 6F introducer sheath.

Conditions

  • Cardiovascular Disease.

Interventions

  • Arstasis Access System (AXERA)Device

    Placement of the AXERA device in the Femoral Artery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Adverse EventsTime frame: Procedure through 30 day follow-up.
  2. Device SuccessTime frame: Day 1-Day of Procedure.

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Heart Center Research, LLC

    Huntsville, Alabama

  • Arkansas Heart Hospital

    Little Rock, Arkansas

  • Scripps Green

    La Jolla, California

14 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.